Prostate CancerPhase 3NCT00036543
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
A Phase 3 study testing Atrasentan in people with Prostate Cancer, run by Abbott at 232 sites in 18 countries.
Trial summary
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer. Read more about this study
- Who is it for?
- Ages 19 years and older, men only
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- Atrasentan
- How many people
- 1,000 participants
- Where
- 232 sitesin 18 countries
- Study dates
- May 2001to not given
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of prostate cancer.
- Rising PSA while on hormonal therapy or following surgical castration.
- Documented evidence of metastatic disease.
Who cannot join
- Have received cytotoxic chemotherapy.
- Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.
Trial locations and contacts
232 sites in 18 countries.
232 sites in 18 countries
United States79 sites
Albany Medical Center South Clinical Campus
Albany, New York, 12208-3499
Urologic Associates of Allentown
Allentown, Pennsylvania, 18103
Alaska Clinical Research Center, LLC
Anchorage, Alaska, 99508
Winship Cancer Institute Emory University
Atlanta, Georgia, 30322
Sandy Springs Urology
Atlanta, Georgia, 30328
Dreyer Medical Clinic
Aurora, Illinois, 60506
South Fl Medical Research
Aventura, Florida, 33180
Johns Hopkins Oncology Center
Baltimore, Maryland, 21231-1000
Billings Oncology Associates
Billings, Montana, 59101
HemOnCare, PC
Brooklyn, New York, 11235
University Of Vermont
Burlington, Vermont, 05403
The University Of North Carolina At Chapel Hill
Chapel Hill, North Carolina, 27599-7235
Blumenthal Cancer Center
Charlotte, North Carolina, 28203
Wyoming Research Foundation
Cheyenne, Wyoming, 82001
Progressive Care, S.C.
Chicago, Illinois, 60631
Weiss Memorial Hospital
Chicago, Illinois, 60640
Robin V. Smith, MD
Chula Vista, California, 91910
Dept of Veteran's Affairs North Texas Healthcare System
Dallas, Texas, 75216
Ntouch Research Corporation
Dallas, Texas, 75230
Urologic Associates, Pc
Davenport, Iowa, 52807
Atlanta Va Medical Center
Decatur, Georgia, 30033
Urology Associate, Pc
Denver, Colorado, 80210
Iowa Urology
Des Moines, Iowa, 50309
Oregon Urology Specialists
Eugene, Oregon, 97401
Evanston Hospital Kellogg Cancer Center
Evanston, Illinois, 60201
Welborn Clinic
Evansville, Indiana, 47713
Clinical Physiology Associates
Fort Myers, Florida, 33916
Urology Associate Of Central California
Fresno, California, 93720
South Valley Medical Plaza
Gilroy, California, 95020-3535
The Urology Center
Greensboro, North Carolina, 27401
The Medical Oncology Group
Gulfport, Mississippi, 39501
Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Urology Centers Of Alabama
Homewood, Alabama, 35205
Kansas University Medical Center
Kansas City, Kansas, 66160-7390
San Diego Urology Center
La Mesa, California, 91942
Urological Associates Of Lancaster
Lancaster, Pennsylvania, 17604-3200
Arkansas Urologial Associates, PA
Little Rock, Arkansas, 72205
UCLA School Of Medicine
Los Angeles, California, 90095-1738
Midwest Research Specialists, LLC
Milwaukee, Wisconsin, 53209
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Urology Associates
Nashville, Tennessee, 37209
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-2765
Ochsner Clinic, Department of Urology
New Orleans, Louisiana, 70121
Advanced Research Institute
New Port Richey, Florida, 34652
Beth Israel Medical Center
New York, New York, 10003
NYU Medical Center
New York, New York, 10016
Nyack Hospital
Nyack, New York, 10960
Albert Einstein Medical Center
Philadelphia, Pennsylvania, 19141
University Of Pittsburgh
Pittsburgh, Pennsylvania, 15232
Nevada Urology Associate
Reno, Nevada, 89509
Virginia Urology Center
Richmond, Virginia, 23230
Mayo Clinic
Rochester, Minnesota, 55905
Rochester General Hospital
Rochester, New York, 14621
Mid Atlantic Clinical Research
Rockville, Maryland, 20850
Michigan Institute Of Urology, Pc
Saint Clair Shores, Michigan, 48081
Lakeside Urology, PC
Saint Joseph, Michigan, 49085
St. Joseph Oncology
Saint Joseph, Missouri, 64507
Anthony Middleton, M.D.
Salt Lake City, Utah, 84102
Western Urological Clinic
Salt Lake City, Utah, 84107
Uthscsa
San Antonio, Texas, 78229
Hillcrest Urological Medical Group, Inc.
San Diego, California, 92103
Urology Associates Of San Luis Obispo
San Luis Obispo, California, 93405
Pacific Clinical Research
Santa Monica, California, 90404
Urology Treatment Center
Sarasota, Florida, 34239
Seattle Urological Associates
Seattle, Washington, 98104
University Of Washington School Of Medicine
Seattle, Washington, 98109-1023
Jeffrey Frankel, M.D.
Seattle, Washington, 98166-3059
Regional Urology
Shreveport, Louisiana, 71106
LSUHSC
Shreveport, Louisiana, 71130
Washington University
St Louis, Missouri, 63110
St. Vincent's Medical Center - Staten Island
Staten Island, New York, 10310
Madigan Army Medical Center
Tacoma, Washington, 98431
Southeastern Urological Center, P.A.
Tallahassee, Florida, 32308
Scott & White Memorial Hospital
Temple, Texas, 76508
Albert Einstein College of Medicine
The Bronx, New York, 10461
Western Clinical Research, Inc.
Torrance, California, 90505-4763
Advanced Clinical Trials
Tucson, Arizona, 85712
Urologic Specialists Of Oklahoma, Inc.
Tulsa, Oklahoma, 74104-5433
Center for Urologic Care
West Reading, Pennsylvania, 19611
Canada26 sites
The Male Health Centres
Barrie, Ontario, L4M 4S5
Burlington Professional Centre
Burlington, Ontario, L7N 3V2
The Urology Resource Centre
Burlington, Ontario, L7S 1V2
Tom Baker Cancer Center
Calgary, Alberta, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Service Radio-Oncologie, Chus
Fleurimont, Quebec, J1H 5N4
Queen Elizabeth II Health Sciences Center
Halifax, Nova Scotia, B3H 2Y9
Wilson Urology
Kelowna, British Columbia, V1Y 2H4
Valley Professional Centre
Kentville, Nova Scotia, B4N 4K9
Kingston General Hospital
Kingston, Ontario, K7L 2V7
Probidity Medical Research
Kitchener, Ontario, N2M 5N6
London Health Sciences Centre
London, Ontario, N6A 4G5
Quest Clinical Trials
Markham, Ontario, L6B 1A1
Hopital Notre-Dame
Montreal, Quebec, H2L 4M1
Royal Victoria Hospital
Montreal, Quebec, H3A 1A1
Walk-In Clinic
North Bay, Ontario, P1B 4Z2
Jack Barkin, M.D.
North York, Ontario, M6A 3B5
The Male Health Centres
Oakville, Ontario, L6H 3P1
Ultramed
Pointe-Claire, Quebec, H9R 4S3
Chuq Pavillon Hotel-Dieu
Québec, Quebec, G1R 2J6
Dr. Cal Andreou
Surrey, British Columbia, V3V 1N1
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
Vancouver Hospital & Health Sciences Centre
Vancouver, British Columbia, V5Z 3J5
Dr. P. J. Pommerville, Inc.
Victoria, British Columbia, V8T5G1
Dr. Gary Steinhoff, Clinical Research
Victoria, British Columbia, V8V 3N1
Abbott Clinic
Winnipeg, Manitoba, R3C 1V8
United Kingdom26 sites
Aberdeen Royal Infirmary
Aberdeen, AB9 2ZB
Clatterbridge Centre For Oncology
Bebington, WIRRAL, CH63 4JY
Institute Of Cancer Studies - University of Birmingham
Birmingham, B15 2TT
St Lukes Hospital
Bradford, West Yorkshire, BD5 0NA
Royal Sussex County Hospital
Brighton, BN2 5BE
Southmead Hospital
Bristol, BS10 5NB
Addenbrookes Hospital
Cambridge, CB2 2QQ
St Richard'S Hospital
Chichester, PO19 4SE
Leighton Hospital
Crewe, CW1 4QJ
Western General Hospital
Edinburgh, Scotland, EH4 2XU
Royal Devon And Exeter Hospital
Exeter, Devon, EX2 5DW
Gartnavel General Hospital
Glasgow, G12 0YN
Glasgow Royal Infirmary
Glasgow, G31 2ER
Northwick Park Hospital
Harrow, Middlesex, HA1 3UJ
Freeman Hospital
High Heaton, NE7 7HH
St Batholomew'S Hospital
London, EC1A 7BE
Royal Free Hospital
London, NW3 2QG
Clinical Research Centre - St Georges Hospital
London, SW17 0QT
Nottingham City Hospital
Nottingham, NG5 1PB
Derriford Hospital
Plymouth, PL6 8 DH
Hope Hospital
Salford, M6 8HD
Royal Hallamshire Hospital
Sheffield, S10 1JF
Southampton General
Southampton, SO16 6YD
Lister Hospital
Stevenage, Hertfordshire, SG1 4AB
The Institute Of Cancer Research - Royal Marsden Hospital
Sutton, Surrey, SM2 5PT
Taunton And Somerset Hospital
Taunton, Somerset, TA1 5DA
Germany15 sites
Krankenhaus Am Urban
Berlin, 10967
Allgemeines Krankenhaus Urologie
Celle, 29223
Universitätsklinikum Carl Gustav Carus an der
Dresden, 01307
Universitätsklinikum Urologie
Essen, 45147
Universitätsklinkum
Freiburg im Breisgau, 79106
Allgemeines Krankenhaus Barmbek
Hamburg, 22291
Klinik Und Poliklinik für Urologie und Kinder
Homburg / SAAR, 66421
Universitutsklinikum Lubeck Urologie
Lübeck, 23538
Universitätsklinikum Mannheim
Mannheim, 68135
Urologische Klinik Und Poliklinik Grosshadern
München, 81377
Klinikum Rechts Der Isar
München, 81675
Universitätsklinikum
Münster, 48129
Städtische Kliniken, Urologie
Offenbach, 63069
Universitat Ulm
Ulm, 89070
Klinikum Wuppertal GmbH
Wuppertal, 42283
Australia10 sites
St Vincent's Clinic
Darlinghurst, New South Wales, 2010
Repatriation General Hospital
Daws Park, South Australia, 5041
Peter Maccallum Cancer Institute
East Melbourne, Victoria, 3002
Royal Brisbane Hospital
Herston, Queensland, 4029
Bayside Urology
Mentone, Victoria, 3194
Hollywood Specialist Centre
Nedlands, Western Australia, 6009
Royal Melbourne Hospital
Parkville, Victoria, 3050
Prince Of Wales Hospital
Randwick, New South Wales, 2031
Westmead Public Hospital
Westmead, New South Wales, 2145
Princess Alexandra Hospital
Woolloongabba, QLD 4102
Spain10 sites
Hospital Juan Canalejo
A Coruña, 15006
Fundacion Puigvert
Barcelona, 08025
Hospital Vall D'Hebron
Barcelona, 08035
Hospital de Galdakao
Galdakao-Vizcaya, 48960
Hospital Gregorio Maranon
Madrid, 28007
Clinica Puerta De Hierro
Madrid, 28035
Hospital 12 De Octubre
Madrid, 28041
Hospital Carlos Haya
Málaga, 29009
Hospital Marques De Valdecilla
Santander, 39008
Instituto Valenciano De Oncologia
Valencia, 46009
South Africa9 sites
Constantiaberg Medi-Clinic
Cape Town, 7081
University Of Stellenbosch
Cape Town
University Of Natal - Nelson R Mandela School of Medicine
Durban, 4013
Kenridge St Joseph Wingl
Parktown, 2010
Mediclinic Hospital
Petermaritzburg, 3201
Medi-Clinic Hospital
Pietermaritzburg, 3201
Medical Centre
Pietermaritzburg, 3201
Pretoria Urology Hospital
Pretoria, 0083
Pretoria Academic Hospital
Pretoria
Sweden9 sites
Sahlgrenska University Hospital
Gothenburg, 41345
Helsingborg Hospital
Helsingborg, 251 87
Linkoping University Hospital
Linköping, 501 85
Lund University Hospital
Lund, 221 85
Malmo University Hospital MAS
Malmö, 205 02
Orebro Regional Hospital
Örebro, 701 85
Karolinska Hospital
Stockholm, 171 76
Umea University Hospital
Umeå, 901 85
Uppsala University Hospital
Uppsala, 751 85
Belgium8 sites
A.Z. Middelheim
Antwerp, 2020
AZ Middelheim
Antwerp, 2020
A Z St Jan
Bruges, 8000
University Hospital Erasme
Brussels, 1070
Uz Gent
Ghent, 9000
Virga Jesse Hospital
Hasselt, 3500
C.H.U. Liege
Liège, 4000
St-Elisabeth Ziekenhuis
Turnhout, 2300
Netherlands8 sites
Amc
Amsterdam, 1105 AZ
Rijnstate Hospital
Arnhem, 6815 AD
Medisch Spectrun Twente
Enschede, 7500 KA
Atrium Heerlen
Heerlen, 6401 CX
University Hospital Maastricht
Maastricht, 6229 HX
University Hospital Rotterdam
Rotterdam, 3015 GD
St Franciscus Gasthuis
Rotterdam, 3045 PM
University Hospital Utrecht
Utrecht, 3584 CX
France7 sites
CHU Hôpital Côte De Nacre
Caen, 14033
Hôpital Henri Mondor
Créteil, 94010
CHU de Bicêtre
Le Kremlin-Bicêtre, 94275
Hopital Bichat Claude Bernard
Paris, 75018
Hopital De Pontchaillou
Rennes, Cedex, 35033
Hôpital Foch
Suresnes, 92151
Hopital De Rangueil
Toulouse, Cedex, 31043
Italy6 sites
Clinica Urologica I - Università di Bari
Bari, 70124
Istituto Nazionale per la Ricerca sul Cancro -IST
Genoa, 16132
Istituto Europeo di Oncologia
Milan, 20141
Clinica Urologica - Università Di Milano
Milan, 20142
Istituto di Urologia
Padova, 35128
Policlinico G. B. Rossi
Verona, 37134
Poland5 sites
Katedra I Klinika Urologi AM
Gdansk, 80-742
Katedra i Klinika Urologii - Akademia Medyczna w Gdansku
Gdansk, 80-742
Samodzielny Publiczny Zaklad Opieki
Katowice, 40-073
Szpital Kliniczny Dzieciatka Jezus
Warsaw, 02-034
Akademia Medyczna we Wroclawiu
Wroclaw, 50-043
Austria3 sites
Universitatsklinik Innsbruck
Innsbruck, A-6020
Urologische Abteilung
Linz, A-4010
Landesklinik fur Urologie und Andrologie
Salzburg, A-5020
Greece3 sites
'Alexandra' Hospital
Athens, 115 27
Pe.Pa.G.N.I Hospital
Heraklion, 711 10
G. Genimatas Hospital
Thessaloniki, 546 35
Ireland3 sites
Tallaght Hospital
Dublin, 24
St Vincent'S Hospital
Dublin, 4
Mater Misericordiae Hospital
Dublin, 7
Switzerland3 sites
Zentrum fur Onkologie, Hämatologie und
Aarau, 5001
Inselspital, Universität Bern
Bern, 3010
Chefarzt Urologische Klinik - Universitätsspital Zürich
Zurich, 8091
New Zealand2 sites
Canterbury Urology Research Trust
Christchurch
Promed Urology Ltd.
Tauranga
About this study
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
- Conditions
- Prostate Cancer
- Being tested
- Atrasentan
- Keywords
- Hormone-Refractory, Prostate Cancer
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AtrasentanDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary objective of this study is to evaluate safety and efficacy as measured by time-to-disease progression
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2002 (estimated)
- Study startMay 2001
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 1,000 participants
Sponsor and investigators
- Lead sponsor
- Abbott
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Darryl Sleep, M.D., Study director, Abbott
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00036543
- Sponsor's protocol ID
- M00-211
- Status last verified
- Aug 2006
- First submitted
- 10 May 2002
- Last updated
- 15 Aug 2006
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2006. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
- ClinicalTrials.gov ID
- NCT00036543
- Acronym / sponsor ID
- M00-211
- Conditions
- Prostate Cancer
- Keywords
- Hormone-Refractory, Prostate Cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,000 participants
- Lead sponsor
- AbbottIndustry (pharma, biotech, devices)
- Study start
- May 2001
- First posted
- 13 May 2002 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
Who may qualify
- Ages
- 19 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Diagnosis of prostate cancer.
- Rising PSA while on hormonal therapy or following surgical castration.
- Documented evidence of metastatic disease.
Key exclusion criteria (2 listed)
- Have received cytotoxic chemotherapy.
- Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Atrasentan | Drug | – |
Primary outcome
The primary objective of this study is to evaluate safety and efficacy as measured by time-to-disease progression
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2006.
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Darryl Sleep, M.D. study director
Abbott
232 sites in 18 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Atrasentan in people with Prostate Cancer, run by Abbott at 232 sites in 18 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Aug 2006. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 232 sites in United States, Canada, United Kingdom, Germany, Australia and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary objective of this study is to evaluate safety and efficacy as measured by time-to-disease progression. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2006.